A Multicenter, Observational, Non-interventional Registry Designed to Collect Clinical Data in Chinese Patients Who Have Received CUBICIN Treatment Under Condition of Actual Usage in Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Daptomycin (Primary)
- Indications Gram-positive infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2012 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 28 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.